Baker McKenzie has advised a diverse group of over 90 shareholders on the sale of shares in APEIRON Biologics AG to Ligand Pharmaceuticals Incorporated.
Apeiron, a leading biotechnology company specialized in the development of immunotherapies for the treatment of cancer and other serious diseases, will strengthen its position in the international market through this transaction. Baker McKenzie advised and supported over 90 shareholders of APEIRON Biologics AG in all legal aspects of this complex transaction. The closing took place mid-July 2024.
Gerhard Hermann, partner at Baker McKenzie and head of the transaction team, commented: "We are proud to have advised the shareholders of APEIRON Biologics AG on this landmark transaction."
The Baker McKenzie team included M&A, corporate, tax and intellectual property experts who together ensured that all aspects of the transaction were executed seamlessly and efficiently.
Team:
Lead: Gerhard Hermann (Partner, Vienna), Claudia Fochtmann-Tischler (Partner, Vienna)
Corporate/M&A: Ladislav Bulajcsik (Senior Associate, Vienna), Klara Kastner (Associate), Jakob Jaritz (Junior Associate, Vienna), Siba Auf (Junior Associate, Vienna), Constantin Huber (Law Clerk, Vienna)
Employment: Andrea Haiden (Senior Associate, Vienna),
Tax: Philipp Stanek (Counsel, Vienna)
IP/IT: Lukas Feiler (Partner, Vienna) Silvia Grohmann (Associate)
Other law firms involved:
Consulting for APEIRON Biologics AG:
Corporate: Dorda (Brogyanyi Christoph, Burian-Kerbl Clemens)
IP: Geistwert (Constantin Kletzer)
Consulting Ligand Inc:
McDermott Will & Emery (Uwe Goetker, Sebastian Bonk)
E+H (Alric Ofenheimer, Helena Neuner)